CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03108131
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:45.436798+00:00
Published At: 2025-05-28T00:00:00+00:00
Record Updated At: 2025-05-28
Results Posted At: 2025-05-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Skin Squamous Cell Carcinoma", "Appendix Adenocarcinoma", "Rare Lesion", "Locally Advanced Malignant Neoplasm", "Locally Advanced Skin Squamous Cell Carcinoma", "Metastatic Malignant Neoplasm", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Small Intestinal Adenocarcinoma", "Rare Neoplastic Syndrome", "Refractory Malignant Neoplasm", "Stage IV Small Intestinal Adenocarcinoma AJCC v8", "Unresectable Malignant Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-28"
protocolSection.identificationModule.nctId: "NCT03108131"
protocolSection.identificationModule.officialTitle: "A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-05-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.